Liquidia Corporation Common Stock (LQDA) Stock
Key stats
- Market cap
- $4.97B
- Price / Earnings ratio
- 33.2x
- EPS (TTM)
- $1.57
- Volume
- Loading
- 52-week high
- $93.61
- 52-week low
- $22.31
Source: third-party data provider, as of November 13, 2026
Compare with LQDA
Recent news

Biotech Beats SPY And QQQ In Market Rout — Now Hims Earnings And Summit’s FDA Test Take Center Stage ‘
Biotech Beats SPY And QQQ In Market Rout — Now Hims Earnings And Summit’s FDA Test Take Center Stage ‘
LQDA

Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?
Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?
LQDA

Liquidia Corporation (LQDA) Earnings Expected to Grow: Should You Buy?
Liquidia Corporation (LQDA) Earnings Expected to Grow: Should You Buy?
LQDA

Stocktwits Wall Street Wrap: Crocs, Liquidia Win Upgrades While SpaceX Competition And Grocery Woes Put AST SpaceMobile, Albertsons Under Pressure
Stocktwits Wall Street Wrap: Crocs, Liquidia Win Upgrades While SpaceX Competition And Grocery Woes Put AST SpaceMobile, Albertsons Under Pressure
LQDA
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 65.76
- MACD 12/26/9
- 1.26
- EMA 9 of MACD
- -0.75
- MACD histogram
- 2.02
- SMA 50
- $49.42
- Price above SMA 50
- EMA 50
- $49.45
- Price above EMA 50
- SMA 200
- $54.56
- Price above SMA 200
- EMA 200
- $49.70
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Biotech Beats SPY And QQQ In Market Rout — Now Hims Earnings And Summit’s FDA Test Take Center Stage ‘
Biotech Beats SPY And QQQ In Market Rout — Now Hims Earnings And Summit’s FDA Test Take Center Stage ‘
LQDA

Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?
Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?
LQDA

Liquidia Corporation (LQDA) Earnings Expected to Grow: Should You Buy?
Liquidia Corporation (LQDA) Earnings Expected to Grow: Should You Buy?
LQDA

Stocktwits Wall Street Wrap: Crocs, Liquidia Win Upgrades While SpaceX Competition And Grocery Woes Put AST SpaceMobile, Albertsons Under Pressure
Stocktwits Wall Street Wrap: Crocs, Liquidia Win Upgrades While SpaceX Competition And Grocery Woes Put AST SpaceMobile, Albertsons Under Pressure
LQDA

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
LQDA

Liquidia shares surge 25% as settlement ends United Therapeutics litigation
Liquidia shares surge 25% as settlement ends United Therapeutics litigation
LQDA

United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%
United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%
LQDA

Liquidia And United Therapeutics Settle; But Only One Stock Skyrocketed
Liquidia And United Therapeutics Settle; But Only One Stock Skyrocketed
LQDA

LQDA Explodes After Hours On Deal Ending Years Of Patent Fight, Keeping YUTREPIA On Market
LQDA Explodes After Hours On Deal Ending Years Of Patent Fight, Keeping YUTREPIA On Market
LQDA

LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law
LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law
LQDA
News tone: automated (AI) classification of the article's content, not a price prediction.
About Liquidia Corporation Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Roger A. Jeffs Ph.D. | CEO & Director | 1962 |
| Mr. Michael Kaseta | COO & CFO | 1976 |
| Mr. Russell Schundler | General Counsel & Corporate Secretary | 1976 |
| Mr. Scott Moomaw | Chief Commercial Officer | 1971 |
| Dr. Rajeev Saggar M.D. | Chief Medical Officer | 1975 |
| Ms. Dana Boyle | Chief Accounting Officer | 1985 |
| Mr. Christian Perez Font | Senior VP, Chief Compliance Officer & Associate General Counsel | — |
| Mr. Michael Post | Senior Vice President of Marketing | — |
| Ms. Sarah Krepp SPHR | Chief Human Resources Officer | 1982 |
| Mr. Jason Adair | Chief Business Officer | 1973 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 65.76
- MACD 12/26/9
- 1.26
- EMA 9 of MACD
- -0.75
- MACD histogram
- 2.02
- SMA 50
- $49.42
- Price above SMA 50
- EMA 50
- $49.45
- Price above EMA 50
- SMA 200
- $54.56
- Price above SMA 200
- EMA 200
- $49.70
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $40.00
- Average
- $61.71
- High
- $87.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -14.6 | +17.9 | ||||||||||
| 2022 | +10.1 | +7.8 | +10.5 | -23.8 | -30.4 | +12.1 | +15.8 | +16.1 | +11.9 | -11.4 | -3.1 | +20.0 |
| 2023 | +8.4 | +18.5 | -7.0 | -4.7 | +21.6 | -9.0 | -1.4 | -11.9 | -9.4 | +4.5 | +8.6 | +65.5 |
| 2024 | +10.8 | +4.1 | +1.6 | -13.9 | -2.3 | -17.2 | -0.9 | -17.9 | +9.9 | +6.2 | +5.2 | +4.7 |
| 2025 | +17.6 | +8.1 | -0.8 | -3.7 | +6.7 | -26.1 | +55.8 | +56.6 | -20.4 | +10.5 | +29.4 | +7.6 |
| 2026 | +35.0 | -29.8 | +22.0 | +4.6 | +62.2 | +35.7 | +6.0 | -18.7 | -54.8 | +61.0 | +31.9 |



